title: [A case of subacute idiopathic interstitial pneumonia resistant to steroids, successfully treated with cyclophosphamide].
abstract: A 47-year-old woman was admitted to our hospital because of dry cough, fever, and subacute, progressive dyspnea. Chest radiography and computed tomography showed ground glass opacities in the lower lung fields. We suspected pneumonia caused by atypical pathogens and administered antibiotics, but they had no effect at all. Histopathologic findings from a transbronchial lung biopsy (TBLB) included intensive infiltration of mononuclear cells and edema on the alveolar wall with no evidence of fibrosis, fibroblasts, hyaline membrane, or granuloma. On the basis of these findings, we suspected interstitial pneumonia, but a surgical lung biopsy was not possible because the patient would not give her consent. After TBLB, corticosteroid was administered repetitively, but dyspnea was deteriorating as the ground glass opacities became more widespread, and tractional bronchiectasis appeared throughout the lung fields. Therefore, we decided to administer cyclophosphamide (CPA). This was very effective: all of her symptoms improved and the ground glass opacities and tractional bronchiectasis disappeared. Though we tapered and then discontinued corticosteroids a few months after CPA, there was no recurrence whatever. No signs suggesting the association of collagen vascular diseases were detected. The effectiveness of CPA in interstitial pneumonia associated with collagen vascular disease is occasionally reported, but the effect on idiopathic interstitial pneumonia, especially in acute and subacute progressive cases, is rarely reported. We think this is an interesting case to consider the availability of CPA in idiopathic interstitial pneumonia with subacute progression.
authors.affiliation: Department of Respiratory Medicine, Haibara General Hospital.
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Ozawa
authors.forename: Masaaki
authors.initials: M
authors.lastname: Ida
authors.forename: Takahumi
authors.initials: T
authors.lastname: Suda
authors.forename: Masato
authors.initials: M
authors.lastname: Katou
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Enomoto
authors.forename: Masato
authors.initials: M
authors.lastname: Fujii
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Nogimura
authors.forename: Kingo
authors.initials: K
authors.lastname: Chida
authors.forename: Hiroyoshi
authors.initials: H
authors.lastname: Nakamura
mesh_terms: D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000494:pharmacology; D003520:Cyclophosphamide / Q000627:therapeutic use*; D004351:Drug Resistance; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D017563:Lung Diseases, Interstitial / Q000188:drug therapy*; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage / Q000494:pharmacology; D020551:Pulse Therapy, Drug; D013256:Steroids / Q000008:administration & dosage / Q000494:pharmacology
chemical_list: D000893:Anti-Inflammatory Agents; D007166:Immunosuppressive Agents; D013256:Steroids; D003520:Cyclophosphamide; D011239:Prednisolone